Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Leukemia|October 16, 2004
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cellsI Ringshausen, T Dechow, F Schneller, et al.
Experimental Hematology|May 17, 2000
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotypeT Decker, F Schneller, M Kronschnabl, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in GermanyK Potthoff, T Dechow, S Lorenzen, et al.
Oncogene|February 11, 2014
Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer modelA Baumgart, P K Mazur, M Anton, et al.
Cancer Medicine|April 2, 2026
Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical TrialH Nückel, T Behlendorf, H Schulz, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registryK Potthoff, H Bläker, T Dechow, et al.
BMC Cancer|July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancerG Sommerhäuser, A Kurreck, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' methodM Haas, D T Waldschmidt, M Stahl, et al.
Pageof 1